Clinical Trials
112 trialsNCT02971501 2026-05-29
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00334815 2026-05-26
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT04042558 2026-05-12
GFPC 06-2018
Centre Francois Baclesse
Phase 2 Completed
NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03133546 2026-02-06
BOOSTER
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT03676192 2025-03-17
To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Celltrion
Phase 3 Completed
NCT00324805 2025-03-03
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT02754882 2024-12-16
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Samsung Bioepis Co., Ltd.
Phase 3 Completed
NCT04325698 2024-10-01
A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
Pfizer
Phase 3 Terminated
NCT00998166 2024-07-30
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
Columbia University
Phase 2 Terminated
NCT04426825 2024-05-21
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT03117049 2024-05-06
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
Ono Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03250832 2024-04-11
CITRINO
Tesaro, Inc.
Phase 1 Completed
NCT01763645 2024-01-11
A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer
Biocad
Phase 3 Completed
NCT04099836 2023-12-26
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Duke University
Phase 2 Terminated
NCT02803203 2023-09-22
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00828009 2023-07-07
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01107626 2023-07-07
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00946712 2023-05-23
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT03713944 2023-03-01
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT00312728 2023-01-06
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Phase 2 Completed
NCT01649947 2022-11-21
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT01562028 2022-08-24
BELIEF
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT00970684 2022-08-16
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00553800 2022-07-12
NSCLC
Fox Chase Cancer Center
Phase 2 Completed
NCT00456261 2022-05-03
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
SCRI Development Innovations, LLC
Phase 2 Completed
NCT04633564 2022-03-16
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Viatris Inc.
Phase 3 Completed
NCT02810457 2022-03-10
AVANA
Centus Biotherapeutics Limited
Phase 3 Completed
NCT00741988 2021-12-15
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00960297 2021-12-06
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00402883 2021-11-09
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00948675 2021-10-29
Study of Participants With Advanced Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT01454102 2021-10-12
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
Phase 1 Completed
NCT02366143 2021-09-23
IMpower150
Hoffmann-La Roche
Phase 3 Completed
NCT00533429 2021-05-13
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
Eli Lilly and Company
Phase 2 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03296163 2021-04-26
STELLA
mAbxience Research S.L.
Phase 3 Completed
NCT00438204 2021-04-13
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
NCT00130728 2021-01-14
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 3 Completed
NCT00295503 2020-10-20
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed